Payment overview · 2025
General Payments
$161.75
10 reported records · 7 companies
Healthcare provider profile · identity verified
Noble B Daniel, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · STUTTGART, AR · NPI 1407812126
Verified facts
What the public records show
CMS Open Payments records show Noble B Daniel, M.D. received $161.75 in general payments during 2025 across 10 reported records.
Novo Nordisk Inc accounted for 18.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Trelegy Ellipta, Ubrelvy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Ubrelvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $29.91 | 18.5% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $29.15 | 18.0% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $28.82 | 17.8% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $20.40 | 12.6% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $19.65 | 12.2% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $18.27 | 11.3% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $15.55 | 9.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $161.75 | 10 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $29.91 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $29.91 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $29.15 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $28.82 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $20.40 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $19.65 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $18.27 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $18.27 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $15.55 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $14.26 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $13.50 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 64 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
64 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 639 | 105 |
| Amlodipine Besylate | Amlodipine Besylate | 455 | 75 |
| Metoprolol Succinate | Metoprolol Succinate | 435 | 59 |
| Potassium Chloride | Potassium Chloride | 428 | 71 |
| Furosemide | Furosemide | 397 | 69 |
| Losartan Potassium | Losartan Potassium | 387 | 63 |
| Omeprazole | Omeprazole | 366 | 69 |
| Levothyroxine Sodium | Levothyroxine Sodium | 322 | 47 |
| Lisinopril | Lisinopril | 307 | 56 |
| Eliquis | Apixaban | 283 | 32 |
| Gabapentin | Gabapentin | 283 | 46 |
| Pantoprazole Sodium | Pantoprazole Sodium | 281 | 46 |
| Metoprolol Tartrate | Metoprolol Tartrate | 216 | 44 |
| Simvastatin | Simvastatin | 205 | 36 |
| Tamsulosin Hcl | Tamsulosin Hcl | 195 | 33 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 185 | 33 |
| Tramadol Hcl | Tramadol Hcl | 177 | 35 |
| Meloxicam | Meloxicam | 169 | 44 |
| Zolpidem Tartrate | Zolpidem Tartrate | 156 | 24 |
| Carvedilol | Carvedilol | 154 | 24 |
| Alprazolam | Alprazolam | 144 | 26 |
| Clopidogrel | Clopidogrel Bisulfate | 137 | 25 |
| Sertraline Hcl | Sertraline Hcl | 117 | 16 |
| Allopurinol | Allopurinol | 114 | 18 |
| Hydrochlorothiazide | Hydrochlorothiazide | 113 | 22 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 106 | 28 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 104 | 28 |
| Mounjaro | Tirzepatide | 103 | 14 |
| Metformin Hcl | Metformin Hcl | 102 | 25 |
| Spironolactone | Spironolactone | 97 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 94 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 90 | 27 |
| Hydralazine Hcl | Hydralazine Hcl | 86 | 13 |
| Chlorthalidone | Chlorthalidone | 85 | 13 |
| Pregabalin | Pregabalin | 82 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 80 | 12 |
| Clonidine Hcl | Clonidine Hcl | 77 | 19 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 77 | suppressed |
| Famotidine | Famotidine | 75 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 72 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 71 | 11 |
| Jardiance | Empagliflozin | 66 | 15 |
| Ozempic | Semaglutide | 64 | suppressed |
| Nifedipine Er | Nifedipine | 63 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 63 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 61 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 58 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 57 | suppressed |
| Atenolol | Atenolol | 56 | 12 |
| Metformin Hcl Er | Metformin Hcl | 56 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 55 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 54 | 15 |
| Temazepam | Temazepam | 53 | suppressed |
| Mirtazapine | Mirtazapine | 52 | 12 |
| Montelukast Sodium | Montelukast Sodium | 52 | suppressed |
| Estradiol | Estradiol | 49 | 21 |
| Xarelto | Rivaroxaban | 49 | suppressed |
| Nitroglycerin | Nitroglycerin | 47 | 19 |
| Glimepiride | Glimepiride | 46 | suppressed |
| Latanoprost | Latanoprost | 46 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 46 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 44 | 17 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 44 | 28 |
| Nortriptyline Hcl | Nortriptyline Hcl | 44 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 42 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 38 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 38 | suppressed |
| Ondansetron Odt | Ondansetron | 37 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 36 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 36 | suppressed |
| Linzess | Linaclotide | 36 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 36 | 12 |
| Amiodarone Hcl | Amiodarone Hcl | 34 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 34 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 33 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 32 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 32 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 32 | suppressed |
| Tiadylt Er | Diltiazem Hcl | 32 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 31 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 31 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 31 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 30 | 23 |
| Finasteride | Finasteride | 30 | suppressed |
| Haloperidol | Haloperidol | 30 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 29 | suppressed |
| Lovastatin | Lovastatin | 29 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 28 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Ezetimibe | Ezetimibe | 27 | suppressed |
| Clonidine | Clonidine | 26 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 26 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 25 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 25 | suppressed |
| Novolog | Insulin Aspart | 25 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 24 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 23 | suppressed |
| Fentanyl | Fentanyl | 23 | suppressed |
| Memantine Hcl | Memantine Hcl | 23 | suppressed |
| Prednisone | Prednisone | 23 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 21 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 21 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 21 | suppressed |
| Ranolazine Er | Ranolazine | 21 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 20 | 18 |
| Midodrine Hcl | Midodrine Hcl | 19 | suppressed |
| Timolol Maleate | Timolol Maleate | 19 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 19 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 19 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 18 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 18 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 18 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 18 | suppressed |
| Mupirocin | Mupirocin | 18 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 18 | suppressed |
| Sucralfate | Sucralfate | 18 | suppressed |
| Valsartan | Valsartan | 18 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 17 | suppressed |
| Hydroxyurea | Hydroxyurea | 17 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 17 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Azithromycin | Azithromycin | 16 | 14 |
| Digoxin | Digoxin | 16 | suppressed |
| Fluconazole | Fluconazole | 16 | 14 |
| Levemir | Insulin Detemir | 16 | suppressed |
| Metolazone | Metolazone | 16 | suppressed |
| Sulfasalazine | Sulfasalazine | 16 | suppressed |
| Carbamazepine | Carbamazepine | 15 | suppressed |
| Cephalexin | Cephalexin | 15 | 11 |
| Glipizide | Glipizide | 15 | suppressed |
| Humulin R | Insulin Regular, Human | 15 | suppressed |
| Isosorbide Mononitrate | Isosorbide Mononitrate | 15 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 15 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 15 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 15 | suppressed |
| Clonazepam | Clonazepam | 14 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 14 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 14 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 14 | suppressed |
| Myrbetriq | Mirabegron | 14 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 14 |
| Ubrelvy | Ubrogepant | 14 | suppressed |
| Budesonide | Budesonide | 13 | suppressed |
| Edarbyclor | Azilsartan Med/Chlorthalidone | 13 | suppressed |
| Lansoprazole | Lansoprazole | 13 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 13 | suppressed |
| Methocarbamol | Methocarbamol | 13 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 13 | suppressed |
| Trulicity | Dulaglutide | 13 | suppressed |
| Acebutolol Hcl | Acebutolol Hcl | 12 | suppressed |
| Amoxicillin | Amoxicillin | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Arformoterol Tartrate | Arformoterol Tartrate | 12 | suppressed |
| Bupropion Xl | Bupropion Hcl | 12 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Indapamide | Indapamide | 12 | suppressed |
| Methotrexate | Methotrexate Sodium | 12 | suppressed |
| Methylprednisolone | Methylprednisolone | 12 | 12 |
| Perphenazine | Perphenazine | 12 | suppressed |
| Propafenone Hcl Er | Propafenone Hcl | 12 | suppressed |
| Risperidone | Risperidone | 12 | suppressed |
| Synthroid | Levothyroxine Sodium | 12 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 11 | suppressed |
| Calcium Acetate | Calcium Acetate | 11 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 11 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 11 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 11 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 11 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $161.75 · 10 records | Novo Nordisk Inc | AREXVY, CAPLYTA, Dexcom G6 Transmitter, OTEZLA, Ozempic, QULIPTA, REPATHA, REXULTI, Rybelsus, TRELEGY ELLIPTA, UBRELVY | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error